相关实验视频

Updated: Jun 25, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

在肺癌PD-1/PD-L1治疗中进行短期预测分析的免疫学分析

Yun Wang¹, Rujia Chen¹, Zhenzhou Guo²

¹Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Road 1095, Wuhan, 1095, 430030, 430030, China.

|July 18, 2024

概括

外围免疫细胞子集可以预测肺癌患者对PD-1/PD-L1抑制剂的反应. 更高的Treg细胞和HLA-DR+ CD4+ T细胞与非完全缓解有关,这表明针对个性化免疫疗法进行免疫分析.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
翻译医学是一种翻译医学.

背景情况:

免疫检查点抑制剂 (ICI),如抗编程细胞死亡-1 (PD-1) 和PD-1-1 (PD-L1) 抗体,改善了肺癌的生存率.
使用PD-L1表达和瘤突变负担等生物标志物,但治疗耐药性和缺乏持久益处仍然存在.
了解肺癌免疫学是克服对免疫调节疗法耐药性的关键.

研究的目的:

研究外围免疫标志物的预测潜力,以预测接受PD-1/PD-L1抑制剂的肺癌患者的治疗疗效.
探索与治疗反应相关的免疫细胞子集变化和表型.

主要方法:

招募了71名接受PD-1/PD-L1抑制剂治疗的肺癌患者和20名健康对照.
进行免疫细胞子集分析 (CD4+ T 细胞,CD8+ T 细胞,B 细胞,NK 细胞,NKT 细胞).
进行了T和B细胞的表型分析和淋巴细胞功能测定.

主要成果:

肺癌患者的免疫细胞子集发生变化,调节性T (Treg) 细胞增加.
在治疗后,观察到CD3+,CD8+T细胞和NKT细胞的增加,CD3+和CD8+T细胞的HLA-DR表达增加.
与完全缓解的患者相比,非完全缓解 (NCR) 的患者的Treg细胞百分比和HLA-DR+ CD4+ T细胞更高.

结论:

免疫细胞子集和表型,特别是Treg细胞,HLA-DR+ CD4+ T细胞和原始CD4+ T细胞,可以预测PD-1/PD-L1治疗肺癌的短期疗效.
这些发现凸显了免疫分析对于个性化治疗策略在肺癌免疫治疗中的重要性.
外周免疫标记分析为优化ICI治疗选择和预测患者结果提供了潜力.

关键词:

在CD4+T细胞中.肺癌是一种肺癌.在PD-1中使用PD-1.在PD-L1中.这些Treg细胞.

更多相关视频

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...